|
Gene: FAIM2 |
Gene summary for FAIM2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | FAIM2 | Gene ID | 23017 |
Gene name | Fas apoptotic inhibitory molecule 2 | |
Gene Alias | LFG | |
Cytomap | 12q13.12 | |
Gene Type | protein-coding | GO ID | GO:0002931 | UniProtAcc | Q9BWQ8 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
23017 | FAIM2 | ATC13 | Human | Thyroid | ATC | 2.56e-35 | 7.10e-01 | 0.34 |
23017 | FAIM2 | ATC5 | Human | Thyroid | ATC | 2.60e-44 | 7.60e-01 | 0.34 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ATC: Anaplastic thyroid cancer | |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:200123335 | Thyroid | ATC | regulation of apoptotic signaling pathway | 206/6293 | 356/18723 | 2.81e-21 | 5.92e-19 | 206 |
GO:2001234210 | Thyroid | ATC | negative regulation of apoptotic signaling pathway | 129/6293 | 224/18723 | 1.26e-13 | 6.46e-12 | 129 |
GO:0097191210 | Thyroid | ATC | extrinsic apoptotic signaling pathway | 125/6293 | 219/18723 | 7.19e-13 | 3.16e-11 | 125 |
GO:2001236210 | Thyroid | ATC | regulation of extrinsic apoptotic signaling pathway | 89/6293 | 151/18723 | 1.43e-10 | 4.40e-09 | 89 |
GO:0070997210 | Thyroid | ATC | neuron death | 176/6293 | 361/18723 | 1.43e-09 | 3.57e-08 | 176 |
GO:190121428 | Thyroid | ATC | regulation of neuron death | 156/6293 | 319/18723 | 9.30e-09 | 1.96e-07 | 156 |
GO:0008625111 | Thyroid | ATC | extrinsic apoptotic signaling pathway via death domain receptors | 50/6293 | 82/18723 | 3.47e-07 | 5.13e-06 | 50 |
GO:005140227 | Thyroid | ATC | neuron apoptotic process | 120/6293 | 246/18723 | 5.41e-07 | 7.75e-06 | 120 |
GO:004352323 | Thyroid | ATC | regulation of neuron apoptotic process | 104/6293 | 212/18723 | 2.16e-06 | 2.58e-05 | 104 |
GO:1902041110 | Thyroid | ATC | regulation of extrinsic apoptotic signaling pathway via death domain receptors | 32/6293 | 49/18723 | 5.63e-06 | 6.00e-05 | 32 |
GO:200123729 | Thyroid | ATC | negative regulation of extrinsic apoptotic signaling pathway | 54/6293 | 97/18723 | 6.41e-06 | 6.68e-05 | 54 |
GO:190121519 | Thyroid | ATC | negative regulation of neuron death | 97/6293 | 208/18723 | 6.19e-05 | 4.73e-04 | 97 |
GO:000293111 | Thyroid | ATC | response to ischemia | 34/6293 | 58/18723 | 8.05e-05 | 6.03e-04 | 34 |
GO:190204212 | Thyroid | ATC | negative regulation of extrinsic apoptotic signaling pathway via death domain receptors | 19/6293 | 31/18723 | 1.45e-03 | 7.47e-03 | 19 |
GO:004352412 | Thyroid | ATC | negative regulation of neuron apoptotic process | 66/6293 | 145/18723 | 1.86e-03 | 9.11e-03 | 66 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FAIM2 | SNV | Missense_Mutation | c.862G>A | p.Glu288Lys | p.E288K | Q9BWQ8 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
FAIM2 | SNV | Missense_Mutation | c.211N>T | p.Ser71Cys | p.S71C | Q9BWQ8 | protein_coding | deleterious(0.05) | benign(0.293) | TCGA-AA-3713-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PR | |
FAIM2 | SNV | Missense_Mutation | rs751246525 | c.839G>A | p.Arg280Gln | p.R280Q | Q9BWQ8 | protein_coding | deleterious(0) | possibly_damaging(0.593) | TCGA-AA-3845-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
FAIM2 | SNV | Missense_Mutation | rs773139598 | c.520N>A | p.Val174Ile | p.V174I | Q9BWQ8 | protein_coding | tolerated(1) | benign(0) | TCGA-AA-A01R-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fluorouracil | PD |
FAIM2 | SNV | Missense_Mutation | c.156C>A | p.Phe52Leu | p.F52L | Q9BWQ8 | protein_coding | tolerated(0.36) | benign(0.003) | TCGA-G4-6322-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | oxaliplatin | PD | |
FAIM2 | SNV | Missense_Mutation | rs145638550 | c.173C>T | p.Ala58Val | p.A58V | Q9BWQ8 | protein_coding | tolerated(0.16) | benign(0.091) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FAIM2 | SNV | Missense_Mutation | novel | c.437N>T | p.Ala146Val | p.A146V | Q9BWQ8 | protein_coding | tolerated(0.12) | benign(0.006) | TCGA-AJ-A3BH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
FAIM2 | SNV | Missense_Mutation | rs201425199 | c.295C>T | p.Arg99Cys | p.R99C | Q9BWQ8 | protein_coding | deleterious(0.01) | benign(0.028) | TCGA-AJ-A3NE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FAIM2 | SNV | Missense_Mutation | rs751246525 | c.839N>A | p.Arg280Gln | p.R280Q | Q9BWQ8 | protein_coding | deleterious(0) | possibly_damaging(0.593) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FAIM2 | SNV | Missense_Mutation | c.927N>T | p.Gln309His | p.Q309H | Q9BWQ8 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |